{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:21:15Z","timestamp":1770222075143,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T00:00:00Z","timestamp":1528243200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00259-018-4056-6","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T13:28:47Z","timestamp":1528291727000},"page":"2071-2078","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients"],"prefix":"10.1007","volume":"45","author":[{"given":"E.","family":"Incerti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Broggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fodor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cuzzocrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Samanes Gajate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mapelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fiorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Dell\u2019Oca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pasetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Calandrino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gianolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Di Muzio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Picchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,6]]},"reference":[{"key":"4056_CR1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2471\/Blt.11.086678","volume":"89","author":"V Delgermaa","year":"2011","unstructured":"Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89:716\u201324. \n                    https:\/\/doi.org\/10.2471\/Blt.11.086678\n                    \n                  .","journal-title":"Bull World Health Organ"},{"key":"4056_CR2","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/sj.bjc.6690105","volume":"79","author":"J Peto","year":"1999","unstructured":"Peto J, Decarli A, La Vecchia C, Levis F, Negri E. The European mesothelioma epidemic. Br J Cancer. 1999;79:666\u201372. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6690105\n                    \n                  .","journal-title":"Br J Cancer"},{"key":"4056_CR3","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/Jco.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636\u201344. \n                    https:\/\/doi.org\/10.1200\/Jco.2003.11.136\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"4056_CR4","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1200\/Jco.20005.14.589","volume":"23","author":"JP Meerbeeck van","year":"2005","unstructured":"van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881\u20139. \n                    https:\/\/doi.org\/10.1200\/Jco.20005.14.589\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"4056_CR5","doi-asserted-by":"publisher","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","volume":"26","author":"P Baas","year":"2015","unstructured":"Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v31\u20139. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv199\n                    \n                  .","journal-title":"Ann Oncol"},{"key":"4056_CR6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/Jto.0000000000000064","volume":"9","author":"P Bovolato","year":"2014","unstructured":"Bovolato P, Casadio C, Bille A, Ardissone F, Santambrogio L, Ratto GB, et al. Does surgery improve survival of patients with malignant pleural mesothelioma? J Thorac Oncol. 2014;9:390\u20136. \n                    https:\/\/doi.org\/10.1097\/Jto.0000000000000064\n                    \n                  .","journal-title":"J Thorac Oncol"},{"key":"4056_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.lungcan.2013.11.026","volume":"83","author":"C Cao","year":"2014","unstructured":"Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83:240\u20135. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2013.11.026\n                    \n                  .","journal-title":"Lung Cancer"},{"issue":"16_suppl","key":"4056_CR8","doi-asserted-by":"publisher","first-page":"7180","DOI":"10.1200\/jco.2005.23.16_suppl.7180","volume":"23","author":"KE Rosenzweig","year":"2005","unstructured":"Rosenzweig KE, Gupta V, Mychalczak B, Krug LM, Flores R, Rusch VW. Hemithoracic radiation therapy and brachytherapy after pleurectomy\/decortication for malignant pleural mesothelioma: results from a 30-year experience. J Clin Oncol. 2005;23(16_suppl):7180. \n                    https:\/\/doi.org\/10.1200\/jco.2005.23.16_suppl.7180\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"4056_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ccm.2012.12.005","volume":"34","author":"AR Haas","year":"2013","unstructured":"Haas AR, Sterman DH. Malignant pleural mesothelioma update on treatment options with a focus on novel therapies. Clin Chest Med. 2013;34:99\u2013111. \n                    https:\/\/doi.org\/10.1016\/j.ccm.2012.12.005\n                    \n                  .","journal-title":"Clin Chest Med"},{"key":"4056_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ctrv.2015.03.011","volume":"41","author":"K Reynders","year":"2015","unstructured":"Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41:503\u201310. \n                    https:\/\/doi.org\/10.1016\/j.ctrv.2015.03.011\n                    \n                  .","journal-title":"Cancer Treat Rev"},{"key":"4056_CR11","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ctrv.2015.09.006","volume":"41","author":"E Marcq","year":"2015","unstructured":"Marcq E, Pauwels P, van Meerbeeck JP, Smits ELJ. Targeting immune checkpoints: new opportunity for mesothelioma treatment? Cancer Treat Rev. 2015;41:914\u201324. \n                    https:\/\/doi.org\/10.1016\/j.ctrv.2015.09.006\n                    \n                  .","journal-title":"Cancer Treat Rev"},{"key":"4056_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejrad.2007.08.010","volume":"64","author":"M Yamamuro","year":"2007","unstructured":"Yamamuro M, Gerbaudo VH, Gill RR, Jacobson FL, Sugarbaker DJ, Hatabu H. Morphologic and functional imaging of malignant pleural mesothelioma. Eur J Radiol. 2007;64:356\u201366. \n                    https:\/\/doi.org\/10.1016\/j.ejrad.2007.08.010\n                    \n                  .","journal-title":"Eur J Radiol"},{"key":"4056_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejrad.2016.11.009","volume":"86","author":"S Kanemura","year":"2017","unstructured":"Kanemura S, Kuribayashi K, Funaguchi N, Shibata E, Mikami K, Doi H, et al. Metabolic response assessment with 18F-FDG-PET\/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma. Eur J Radiol. 2017;86:92\u20138. \n                    https:\/\/doi.org\/10.1016\/j.ejrad.2016.11.009\n                    \n                  .","journal-title":"Eur J Radiol"},{"key":"4056_CR14","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.lungcan.2005.03.007","volume":"49","author":"RM Flores","year":"2005","unstructured":"Flores RM. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer. 2005;49:S27\u201332. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2005.03.007\n                    \n                  .","journal-title":"Lung Cancer"},{"key":"4056_CR15","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00066-010-2150-1","volume":"186","author":"G Lammering","year":"2010","unstructured":"Lammering G, De Ruysscher D, van Baardwijk A, Baumert BG, Borger J, Lutgens L, et al. The use of FDG-PET to target tumors by radiotherapy. Strahlenther Onkol. 2010;186:471\u201381. \n                    https:\/\/doi.org\/10.1007\/s00066-010-2150-1\n                    \n                  .","journal-title":"Strahlenther Onkol"},{"key":"4056_CR16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1378\/chest.114.3.713","volume":"114","author":"F Benard","year":"1998","unstructured":"Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest. 1998;114:713\u201322. \n                    https:\/\/doi.org\/10.1378\/chest.114.3.713\n                    \n                  .","journal-title":"Chest"},{"key":"4056_CR17","first-page":"1144","volume":"43","author":"VH Gerbaudo","year":"2002","unstructured":"Gerbaudo VH, Sugarbaker DJ, Britz-Cunningham S, Di Carli MF, Mauceri C, Treves ST. Assessment of malignant pleural mesothelioma with F-18-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology. J Nucl Med. 2002;43:1144\u20139.","journal-title":"J Nucl Med"},{"key":"4056_CR18","first-page":"1443","volume":"41","author":"DCE Ng","year":"2000","unstructured":"Ng DCE, Hain SF, O\u2019Doherty MJ, Dussek J. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med. 2000;41:1443\u20134.","journal-title":"J Nucl Med"},{"key":"4056_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1067\/mtc.2000.106529","volume":"120","author":"DB Schneider","year":"2000","unstructured":"Schneider DB, Clary-Macy C, Challa S, Sasse KC, Merrick SH, Hawkins R, et al. Positron emission tomography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2000;120:128\u201333. \n                    https:\/\/doi.org\/10.1067\/mtc.2000.106529\n                    \n                  .","journal-title":"J Thorac Cardiovasc Surg"},{"key":"4056_CR20","unstructured":"Gregianin M, Dei Rossi F, Cracco E, Zaccaria A, Canton A, Pagan V. PET\/CT in the preoperative evaluation of patients with malignant pleural mesothelioma (MPM). Eur J Nucl Med Mol Imaging. 2007;34:S142."},{"key":"4056_CR21","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2967\/jnumed.107.042333","volume":"48","author":"RJ Francis","year":"2007","unstructured":"Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial F-18-FDG PET scans. J Nucl Med. 2007;48:1449\u201358. \n                    https:\/\/doi.org\/10.2967\/jnumed.107.042333\n                    \n                  .","journal-title":"J Nucl Med"},{"key":"4056_CR22","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s00066-011-2234-6","volume":"187","author":"A Fodor","year":"2011","unstructured":"Fodor A, Fiorino C, Dell\u2019Oca I, Broggi S, Pasetti M, Cattaneo GM, et al. PET-guided dose escalation tomotherapy in malignant pleural mesothelioma. Strahlenther Onkol. 2011;187:736\u201343. \n                    https:\/\/doi.org\/10.1007\/s00066-011-2234-6\n                    \n                  .","journal-title":"Strahlenther Onkol"},{"key":"4056_CR23","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","volume":"31","author":"JD Cox","year":"1995","unstructured":"Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341\u20136. \n                    https:\/\/doi.org\/10.1016\/0360-3016(95)00060-C\n                    \n                  .","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4056_CR24","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.ijrobp.2005.03.041","volume":"63","author":"V Gupta","year":"2005","unstructured":"Gupta V, Mychalczak B, Krug L, Flores R, Bains M, Rusch VW, et al. Hemithoracic radiation therapy after pleurectomy\/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005;63:1045\u201352. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2005.03.041\n                    \n                  .","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4056_CR25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00066-015-0901-8","volume":"192","author":"A Maggio","year":"2016","unstructured":"Maggio A, Cutaia C, Di Dia A, Bresciani S, Miranti A, Poli M, et al. Tomotherapy PET-guided dose escalation. Strahlenther Onkol. 2016;192:102\u20138. \n                    https:\/\/doi.org\/10.1007\/s00066-015-0901-8\n                    \n                  .","journal-title":"Strahlenther Onkol"},{"key":"4056_CR26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ccm.2006.01.004","volume":"27","author":"SD West","year":"2006","unstructured":"West SD, Lee YC. Management of malignant pleural mesothelioma. Clin Chest Med. 2006;27:335\u201354. \n                    https:\/\/doi.org\/10.1016\/j.ccm.2006.01.004\n                    \n                  .","journal-title":"Clin Chest Med"},{"key":"4056_CR27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ijrobp.2009.06.037","volume":"75","author":"MF McAleer","year":"2009","unstructured":"McAleer MF, Tsao AS, Liao ZX. Radiotherapy in malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2009;75:326\u201337. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2009.06.037\n                    \n                  .","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4056_CR28","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s00066-016-1092-7","volume":"193","author":"O Abdel-Rahman","year":"2017","unstructured":"Abdel-Rahman O. Role of postoperative radiotherapy in the management of malignant pleural mesothelioma. Strahlenther Onkol. 2017;193:276\u201384. \n                    https:\/\/doi.org\/10.1007\/s00066-016-1092-7\n                    \n                  .","journal-title":"Strahlenther Onkol"},{"key":"4056_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.radonc.2006.06.002","volume":"80","author":"YC Ung","year":"2006","unstructured":"Ung YC, Yu E, Falkson C, Haynes AE, Stys-Norman D, Evans WK. The role of radiation therapy in malignant pleural mesothelioma: a systematic review. Radiother Oncol. 2006;80:13\u20138. \n                    https:\/\/doi.org\/10.1016\/j.radonc.2006.06.002\n                    \n                  .","journal-title":"Radiother Oncol"},{"key":"4056_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00066-003-1055-7","volume":"179","author":"MW Munter","year":"2003","unstructured":"Munter MW, Nill S, Thilmann C, Hof H, Hoss A, Haring P, et al. Stereotactic intensity-modulated radiation therapy (IMRT) and inverse treatment planning for advanced pleural mesothelioma \u2013 feasibility and initial results. Strahlenther Onkol. 2003;179:535\u201341. \n                    https:\/\/doi.org\/10.1007\/s00066-003-1055-7\n                    \n                  .","journal-title":"Strahlenther Onkol"},{"key":"4056_CR31","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ijrobp.2007.03.011","volume":"69","author":"DC Rice","year":"2007","unstructured":"Rice DC, Smythe WR, Liao ZX, Guerrero T, Chang JY, McAleer MF, et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2007;69:350\u20137. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2007.03.011\n                    \n                  .","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4056_CR32","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.biopha.2013.01.008","volume":"67","author":"C Fuccio","year":"2013","unstructured":"Fuccio C, Spinapolice EG, Ferretti A, Castellucci P, Marzola MC, Trifiro G, et al. F-18-FDG-PET\/CT in malignant mesothelioma. Biomed Pharmacother. 2013;67:539\u201342. \n                    https:\/\/doi.org\/10.1016\/j.biopha.2013.01.008\n                    \n                  .","journal-title":"Biomed Pharmacother"},{"key":"4056_CR33","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1158\/1078-0432.CCR-09-2313","volume":"16","author":"AK Nowak","year":"2010","unstructured":"Nowak AK, Francis RJ, Phillips MJ, Millward MJ, van der Schaaf AA, Boucek J, et al. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res. 2010;16:2409\u201317. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2313\n                    \n                  .","journal-title":"Clin Cancer Res"},{"key":"4056_CR34","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.1016\/j.ejrad.2010.11.006","volume":"81","author":"NG Schaefer","year":"2012","unstructured":"Schaefer NG, Veit-Haibach P, Soyka JD, Steinert HC, Stahel RA. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET\/CT. Eur J Radiol. 2012;81:E19\u201325. \n                    https:\/\/doi.org\/10.1016\/j.ejrad.2010.11.006\n                    \n                  .","journal-title":"Eur J Radiol"},{"key":"4056_CR35","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.lungcan.2009.04.015","volume":"67","author":"P Veit-Haibach","year":"2010","unstructured":"Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B, Stahel RA. Combined FDG-PET\/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer. 2010;67:311\u20137. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2009.04.015\n                    \n                  .","journal-title":"Lung Cancer"},{"key":"4056_CR36","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1245\/s10434-010-1107-z","volume":"17","author":"HY Lee","year":"2010","unstructured":"Lee HY, Hyun SH, Lee KS, Kim BT, Kim J, Shim YM, et al. Volume-based parameter of F-18-FDG PET\/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol. 2010;17:2787\u201394. \n                    https:\/\/doi.org\/10.1245\/s10434-010-1107-z\n                    \n                  .","journal-title":"Ann Surg Oncol"},{"key":"4056_CR37","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s11307-009-0203-6","volume":"11","author":"ST Lee","year":"2009","unstructured":"Lee ST, Ghanem M, Herbertson RA, Berlangieri SU, Byrne AJ, Tabone K, et al. Prognostic value of F-18-FDG PET\/CT in patients with malignant pleural mesothelioma. Mol Imaging Biol. 2009;11:473\u20139. \n                    https:\/\/doi.org\/10.1007\/s11307-009-0203-6\n                    \n                  .","journal-title":"Mol Imaging Biol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-018-4056-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-018-4056-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-018-4056-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T23:06:13Z","timestamp":1559775973000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-018-4056-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,6]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["4056"],"URL":"https:\/\/doi.org\/10.1007\/s00259-018-4056-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,6]]},"assertion":[{"value":"1 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Research Committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}